A study performed at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.
“Human cells infected by chikungunya virus were treated with sofosbuvir, and the drug eliminated the virus without damaging any cells. The drug proved to be 11 times more effective against the virus than against cells,” said Rafaela Milan Bonotto, a coauthor of the study.
An article on the study, signed by Bonotto, Freitas-Junior and collaborators, can be found on the open platform F1000Research. An article on the group’s research relating to yellow fever will be published shortly.
The discovery is highly significant for public health, as a chikungunya epidemic has been forecast for the coming two years in Brazil.
“Drug development is extremely costly and time-consuming. The process takes 12 years on average between the start of research and bringing the drug to market. The cost is on the order of US$1.5 billion or more,” Freitas-Junior said. “Sofosbuvir has been fully approved for human use. This means it can be readied for use against chikungunya in one to three years, for a much lower cost, estimated at approximately US$500,000.”
He noted that chikungunya is a severe disease not only owing to the acute episode itself – causing symptoms similar to those of dengue – but because it can cause complications that include highly debilitating joint pain lasting months or years. The patient may become incapacitated, unable to work and even bedridden.
“So far we have no vaccine, and our diagnostic tools need to be optimized,” he continued. “Sofosbuvir is something concrete that could become a powerful weapon against this virus. The results of our research could enable any interested institutions to begin clinical trials.”
Bonotto said, “We don’t yet know exactly how the drug works in molecular terms. What we discovered was the macroscopic result: elimination of the virus and preservation of cells. The drug has proven effective in treating hepatitis C because it inhibits the protein that synthesizes the viral genome. The same may happen in the case of chikungunya, but the action mechanism must be elucidated.”
The Latest on: Sofosbuvir
via Google News
The Latest on: Sofosbuvir
- Sofosbuvir rids organism of chikungunya and yellow fever viruses on December 19, 2018 at 4:54 am
Human blood cells obtained from the liver. Left: cells infected by chikungunya. Right: cells disinfected by sofosbuvir, whose molecular formula is shown in the center arrow Credit: Bonotto et al. […]
- Drug to Eliminate Chikungunya and Yellow Fever Viruses. on December 19, 2018 at 12:30 am
A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungun... […]
- Sofosbuvir-Based Therapy Safe in Patients With HCV and Certain Cancers on December 14, 2018 at 1:27 pm
Existing data are limited on the treatment of chronic hepatitis C virus (HCV) in patients with cancer. In a study recently published in Nature, researchers sought to evaluate the safety and efficacy o... […]
- European Stakeholders Appeal EPO Ruling to Uphold Gilead's Sofosbuvir Patent on December 7, 2018 at 1:08 pm
Recently, 6 European organizations appealed a European Patent Office (EPO) decision to uphold Gilead Science’s patent on the hepatitis C drug sofosbuvir, sold as Sovaldi. Recently, 6 European organiza... […]
- Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated on December 6, 2018 at 10:30 am
People living with hepatitis C, access to medicines activists, and the medical community around the world "mark" the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), ... […]
- Doctors Without Borders Seeks To Undo Gilead Hep C Patent on December 5, 2018 at 5:03 pm
Law360 (December 5, 2018, 7:51 PM EST) -- Doctors Without Borders and five organizations have appealed the European Patent Office’s decision upholding Gilead Sciences Inc.’s patent for the hepatitis C ... […]
- China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 on December 4, 2018 at 1:42 pm
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 4... […]
- 5 Questions To Ask Your CDMO: #3 — How Do You Control Solid Form? on December 4, 2018 at 8:45 am
A great example of this is sofosbuvir (Sovaldi), a small molecule API developed for the treatment of the hepatitis C virus (HCV). Sofosbuvir has shown incredible efficacy and allowed doctors to cure m... […]
- China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 on December 4, 2018 at 5:52 am
--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Pa... […]
via Bing News